Skip to main content
Premium Trial:

Request an Annual Quote

Shares of Icoria Continue to Slide After Nasdaq s Delisting Notice

NEW YORK, June 24 (GenomeWeb News) - Shares of Icoria were down 8.7 percent at $.21 per share in mid-afternoon trading, one day after the company said it will lose its place on the Nasdaq Small Cap exchange for failing to maintain a stock price above $1.

 

As GenomeWeb News reported yesterday, Nasdaq's Listing Qualifications department sent the company a staff determination notice informing it that it would be delisted from the Small Cap exchange after the opening of business on June 30.

 

The exchange found the company had been delinquent in its obligation to maintain a stock price above $1, as per Marketplace Rule 4310(c)(4), the document said.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.